8 completed. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
Follow Dac: new trials by email Literature Review of Dac trials Research Report on Dac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk Decitabine, Azacitidine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 113 | 2012-11-06 | 2020-12-24 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation - Acute Myeloid Leukemia, Myeloproliferative Neoplasms | Phase 2 | Completed | Hospital Israelita Albert Einstein | 455 | 2012-10-01 | 2016-11-08 |
| Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome tosedostat, cytarabine, decitabine - Acute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | Fred Hutchinson Cancer Center | 34 | 2012-05-01 | 2017-02-15 |
| Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome flow cytometry, DNA methylation analysis, cytogenetic analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 25 | 2010-07-01 | 2019-03-04 |
| Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia Decitabine (USAN, INN) - Thalassemia | Phase 2 | Completed | Carelon Research | 6 | 2008-01-01 | 2014-04-25 |
| Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia decitabine, laboratory biomarker analysis, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2007-05-01 | 2016-06-27 |
| Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Decitabine, Iodine I 131, Recombinant thyrotropin alfa - Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2004-05-01 | 2018-11-29 |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia imatinib mesylate, decitabine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 80 | 2003-01-01 | 2013-01-23 |
Myelodysplastic Syndromes (3) · Anemia, Refractory, with Excess of Blasts (2) · Congenital Abnormalities (2) · Leukemia (2) · Leukemia, Myelomonocytic, Chronic (2) · Adenocarcinoma, Follicular (1) · Anemia, Refractory (1) · Blast Crisis (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thalassemia (1)
National Cancer Institute (NCI) (3) · Carelon Research (1) · Case Comprehensive Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Hospital Israelita Albert Einstein (1) · M.D. Anderson Cancer Center (1)
United States (7) · Brazil (1) · Canada (1)
Brenda Cooper, MD (1) · Elias Jabbour, MD (1) · Fabio P Santos, MD (1) · Jean-Pierre Issa (1) · John Pagel (1) · Nancy Olivieri, MD (1) · Nelson Hamerschlak, MD, PhD (1) · Steven Sherman (1) · William Blum (1) · Yogen Saunthararajah (1)
PMID 20368434, PMID 21700776, PMID 25621498, PMID 28774880, PMID 38319837
N01CM62207 (2), N01CM62202 (1), P30CA015704 (1), P30CA016672 (1), U01HL065238 (1)